FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 275 filers reported holding FATE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.99 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $74,300 | -50.6% | 13,035 | -12.6% | 0.11% | -43.8% |
| Q4 2022 | $150,462 | -64.6% | 14,912 | -21.3% | 0.19% | -54.1% |
| Q3 2022 | $425,000 | -12.0% | 18,946 | -2.7% | 0.42% | -5.9% |
| Q2 2022 | $483,000 | -39.8% | 19,474 | -5.9% | 0.44% | +1.8% |
| Q1 2022 | $802,000 | -15.0% | 20,697 | +28.3% | 0.44% | +32.9% |
| Q4 2021 | $944,000 | +9.9% | 16,138 | +11.3% | 0.33% | +14.3% |
| Q3 2021 | $859,000 | -57.3% | 14,494 | -37.6% | 0.29% | -61.2% |
| Q2 2021 | $2,014,000 | +11.7% | 23,211 | +6.1% | 0.74% | -8.1% |
| Q1 2021 | $1,803,000 | -15.3% | 21,867 | -6.6% | 0.80% | -23.0% |
| Q4 2020 | $2,128,000 | – | 23,407 | – | 1.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |